Block Grant R15HL091503

This $1.44 million Project Grant, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds research to elucidate the role of purinergic signaling in idiopathic pulmonary fibrosis (IPF) pathogenesis. The research, being conducted at the University of California, San Francisco from August 2025 through May 2029, focuses on understanding how the extracellular ATP (eATP) and P2RX4 receptor signaling axis drives fibroblast...

This Project Grant award from the National Center for Advancing Translational Sciences (NCATS) under CFDA 93.350 will provide $463,150 to The Regents of the University of California, San Francisco (UCSF) to establish proof-of-concept for enzyme replacement therapy (ERT) as a lifesaving treatment for sphingosine phosphate lyase insufficiency syndrome (SPLIS), an ultra-rare and often lethal metabolic disorder. The project aims to demonstrate the efficacy of ERT in preserving kidney function and...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Regents of the University of California, San Francisco a Project Grant of $182,060 under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of the senescence marker protein P16INK4A in alveolar epithelial stem cell differentiation during lung injury and repair. The research, conducted at UCSF in San Francisco, California, commenced September 30, 2025, with completion...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $1,376,933 to The Regents of the University of California, San Francisco on August 1, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support research on fibroblast-mediated resolution of basal metaplasia in lung fibrosis through April 30, 2029. The project investigates how alveolar fibroblasts expressing the Hedgehog pathway antagonist (HHIP) promote the restoration of...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a Project Grant of $1,097,760 to The Regents of the University of California, San Francisco (UCSF) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a research initiative titled "Program to Block Age-Related Pulmonary Fibrosis and Restore Lung Regeneration." The award, effective February 15, 2026, with completion targeted for December 31, 2032, supports basic...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded $156,168 to the Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center for research exploring the role of the Hedgehog pathway-primary cilia axis in human lung alveolarization and disease under the Cardiovascular Diseases Research program (CFDA 93.837). The two-year project, initiated August 1, 2025 and concluding July 31, 2027, investigates how hedgehog signaling regulates alveolar...

The University of Pittsburgh received a $1.42 million Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded August 1, 2025, with a completion date of April 30, 2030. The funded research project, titled "Airspace Candida Colonization and Lung Injury" (AIRCCOLIN), will investigate the mechanisms by which Candida species colonization in the lower respiratory tract of critically ill mechanically...

The University of California, San Francisco received a $2.44 million Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program to target the ATP receptor P2RX4 for pulmonary fibrosis. The four-year award beginning July 1, 2021 will support research into medical solutions for pulmonary disease on the battlefield and in veterans. As part of the award, Baylor College of Medicine will receive sub-award funding to conduct clinical...

Federal Project Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded a $638,900 Project Grant to The Regents of the University of California, San Francisco (UCSF) under the Cardiovascular Diseases Research program (CFDA 93.837) on September 15, 2025, with a completion date of June 30, 2030. This research initiative investigates the role of pathologic fibroblast subsets specific to silicosis, a chronic and potentially fatal fibrotic lung disease caused by...